Duan J - Search Results

1

A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity.

Meng F, Li WF, Jung D, Wang CC, Qi T, Shia CS, Hsu RY, Hsieh YC, Duan J. Meng F, et al. Among authors: duan j. Am J Cancer Res. 2021 Jul 15;11(7):3645-3659. eCollection 2021. Am J Cancer Res. 2021. PMID: 34354865 Free PMC article.

2

Potent antitubulin tumor cell cytotoxins based on 3-aroyl indazoles.

Duan JX, Cai X, Meng F, Lan L, Hart C, Matteucci M. Duan JX, et al. J Med Chem. 2007 Mar 8;50(5):1001-6. doi: 10.1021/jm061348t. Epub 2007 Feb 8. J Med Chem. 2007. PMID: 17286393

3

ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1alpha accumulation.

Meng F, Nguyen XT, Cai X, Duan J, Matteucci M, Hart CP. Meng F, et al. Among authors: duan j. Anticancer Drugs. 2007 Apr;18(4):435-45. doi: 10.1097/CAD.0b013e328013ffed. Anticancer Drugs. 2007. PMID: 17351396

4

A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity.

Meng F, Cai X, Duan J, Matteucci MG, Hart CP. Meng F, et al. Among authors: duan j. Cancer Chemother Pharmacol. 2008 May;61(6):953-63. doi: 10.1007/s00280-007-0549-x. Epub 2007 Jul 18. Cancer Chemother Pharmacol. 2008. PMID: 17639393

5

14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment.

Duan JX, Cai X, Meng F, Sun JD, Liu Q, Jung D, Jiao H, Matteucci J, Jung B, Bhupathi D, Ahluwalia D, Huang H, Hart CP, Matteucci M. Duan JX, et al. J Med Chem. 2011 Mar 24;54(6):1715-23. doi: 10.1021/jm101354u. Epub 2011 Feb 22. J Med Chem. 2011. PMID: 21341674

6

Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.

Jung D, Lin L, Jiao H, Cai X, Duan JX, Matteucci M. Jung D, et al. Cancer Chemother Pharmacol. 2012 Mar;69(3):643-54. doi: 10.1007/s00280-011-1741-6. Epub 2011 Oct 1. Cancer Chemother Pharmacol. 2012. PMID: 21964906

7

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.

Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, Duan JX, Cai X, Mowday AM, Guise CP, Maroz A, Anderson RF, Patterson AV, Stachelek GC, Glazer PM, Matteucci MD, Hart CP. Meng F, et al. Mol Cancer Ther. 2012 Mar;11(3):740-51. doi: 10.1158/1535-7163.MCT-11-0634. Epub 2011 Dec 6. Mol Cancer Ther. 2012. PMID: 22147748

8

Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.

Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP. Sun JD, et al. Among authors: duan jx. Clin Cancer Res. 2012 Feb 1;18(3):758-70. doi: 10.1158/1078-0432.CCR-11-1980. Epub 2011 Dec 19. Clin Cancer Res. 2012. PMID: 22184053

9

OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.

Evans K, Duan J, Pritchard T, Jones CD, McDermott L, Gu Z, Toscan CE, El-Zein N, Mayoh C, Erickson SW, Guo Y, Meng F, Jung D, Rathi KS, Roberts KG, Mullighan CG, Shia CS, Pearce T, Teicher BA, Smith MA, Lock RB. Evans K, et al. Among authors: duan j. Clin Cancer Res. 2019 Jul 15;25(14):4493-4503. doi: 10.1158/1078-0432.CCR-19-0551. Epub 2019 Apr 23. Clin Cancer Res. 2019. PMID: 31015346 Free PMC article.

10

Erratum: A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity.

Meng F, Li WF, Jung D, Wang CC, Qi T, Shia CS, Hsu RY, Hsieh YC, Duan J. Meng F, et al. Among authors: duan j. Am J Cancer Res. 2023 Nov 15;13(11):5750. eCollection 2023. Am J Cancer Res. 2023. PMID: 38058837 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,011 results

Search Page